Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of 68 Ga-FAPI PET/CT and 18 F-FDG PET/CT
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.123.265530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Xuetao Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Association, Key Laboratory fo…. Hauptthemen laut MEDLINE: Lymphoma, Quinolines. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Our objective was to compare the diagnostic performance of 68Ga-labeled fibroblast activation protein (FAP) inhibitor (FAPI) and 18F-labeled FDG PET/CT in diagnosing lymphomas and to characterize the influence of FAP and glycolytic markers on tracer uptake by involved lesions.
Methods
Participants with different lymphoma subtypes who were prospectively recruited from May 2020 to December 2021 underwent 68Ga-FAPI and 18F-FDG PET/CT. Immunohistochemistry was performed to evaluate FAP, hexokinase 2, and glucose transporter 1 (GLUT1) expression, and the paired-samples t test and Wilcoxon signed-rank test were used to compare parameters. The correlation between the immunochemistry results and tracer uptake was determined by the Spearman rank correlation coefficient.
Results
In total, 186 participants (median age, 52 y [interquartile range, 41-64 y]; 95 women) were included. Dual-tracer imaging produced 3 types of imaging profiles. 18F-FDG PET possessed a higher staging accuracy (98.4%) than 68Ga-FAPI PET (86.0%). In 5,980 lymphoma lesions, 18F-FDG PET/CT detected more nodal (4,624 vs. 2,196) and extranodal (1,304 vs. 845) lesions than 68Ga-FAPI PET/CT. Additionally, 52 68Ga-FAPI-positive/18F-FDG-negative lesions and 2,939 68Ga-FAPI-negative/18F-FDG-positive lesions were observed. In many lymphoma subtypes, semiquantitative evaluation revealed no significant differences in SUVmax or target-to-liver ratios between 68Ga-FAPI and 18F-FDG PET/CT (P > 0.05). Interestingly, GLUT1 and hexokinase 2 were overexpressed both in lymphoma cells and in the tumor microenvironment, whereas FAP was expressed only in stromal cells. FAP and GLUT1 expression correlated positively with 68Ga-FAPI SUVmax (r = 0.622, P = 0.001) and 18F-FDG SUVmax (r = 0.835, P < 0.001), respectively.
Conclusion
68Ga-FAPI PET/CT was inferior to 18F-FDG PET/CT in diagnosing lymphomas with low FAP expression. However, the former may supplement the latter and help reveal the molecular profile of lymphomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Association, Key Laboratory for Research and Evaluation of Radiopharmaceuticals, National Medical Pr…
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
Zitieren
APA
Chen, X., Wang, S., Lai, Y., Wang, G., Wei, M., Jin, X., Ding, J., Zhang, Y., Shi, Y., Wang, F., Zhu, H., Yang, Z., & Wang, X. (2023). Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of 68 Ga-FAPI PET/CT and 18 F-FDG PET/CT. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265530
Vancouver
Chen X, Wang S, Lai Y, Wang G, Wei M, Jin X, et al. Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of 68 Ga-FAPI PET/CT and 18 F-FDG PET/CT. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.265530
BibTeX
@article{Chen2023,
author = {Chen, Xuetao and Wang, Shuailiang and Lai, Yumei and Wang, Guochang and Wei, Maomao and Jin, Xiao and Ding, Jin and Zhang, Yan and Shi, Yunfei and Wang, Feng and Zhu, Hua and Yang, Zhi and Wang, Xuejuan},
title = {Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of 68 Ga-FAPI PET/CT and 18 F-FDG PET/CT},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.123.265530}
}
EUVIMED